EBMT 2023 | Real-world outcomes of patients with R/R B-ALL treated with blinatumomab and inotuzumab ozogamicin
Ankita Sen, MD, BC Cancer, Vancouver, Canada, shares the results of a retrospective study evaluating the real-world outcomes of adult patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) treated with blinatumomab and/or inotuzumab ozogamicin, comparing the findings with previously published data. The study reported that using blinatumomab pre-transplant led to higher complete remission (CR) rate than using the agent post-transplant. In addition, in patients who were treated with both agents, using blinatumomab first led to higher CR rates. Overall, the findings from this study correlated with previously published data and suggest that using blinatumomab followed by inotuzumab ozogamicin might be an effective strategy for patients with R/R B-ALL. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Dr Yasser Abou Mourad: Consulting and AD boards for Amgen and Pfizer;
Dr Shanee Chung: honoraria from Takeda, Astellas, Novartis;
Dr Kevin Hay: Research funding – Janssen, Advisory boards – Kite/Gilead, BMS, Novartis, Janssen;
Dr Heather Sutherland: consultancy funding from Amgen;
Rest: nothing to declare.
